- Prostate Cancer news are updated once a hour
- We deliver news from more than 500 sources on prostate cancer
NewsAdvertisers: |
A place of hope, not doom... But I saw how the hospice can bring out the best in people. He opened up to his family and his quality of life in his last 18 months was first class. "So many people who are ill die at home alone or in a hospital bed somewhere being completely ignored. The hospice seemed to be a beacon of hope and great support, and I decided that one day I would get involved in some way." Shortly after this, Mr Nagler, who is also a Hertsmere representative on the Hertfordshire Police Authority, became a trustee of the hospice, and last year, was made chairman. As chairman, Mr Nagler oversees its current struggle to overcome a £400,000 deficit and raise enough funds to keep its valuable work going. The hospice, in Peace Drive, Watford, is currently looking at ways to bridge a funding gap. It needs to reduce its costs and cut back on expenses, such as cleaning bills. Its annual budget is £3 million, with just under 20 per cent of that money coming from Hertsmere Primary Care Trust (PCT) and Watford and Three Rivers PCT. This amounts to about £550,000, so the hospice has to rely on the community to raise the remaining £2.5 million. But Mr Nagler is not panicking about the shortfall. "We believe we will get the money as the community are always very supportive," he said. Last month a foundation set up by a S... CFD Therapeutics Formed to Advance Monoclonal Antibodies for ......
Genomics and Proteomics - CFD Therapeutics Formed to Advance Monoclonal Antibodies for Cancer
News
Headlines
Interviews
Market Reports
Company Focus
This Weeks News
This Months News
Submit a Press Release
CFD Therapeutics Formed to Advance Monoclonal Antibodies for Cancer
Date Posted: Friday, March 31, 2006
Options:
Print
diaDexus, Inc. and Biotechnology Value Fund L.P. (BVF) have jointly announced the formation of a spin-out company, CFD Therapeutics, Inc., to develop cancer therapeutics stemming from discoveries made previously by diaDexus. CFD will specifically focus on the development of therapeutic monoclonal antibodies directed against proprietary ovarian, pancreatic, breast, colon, prostate and lung cancer targets licensed from diaDexus. BVF has made an initial investment in CFD, through which it has assumed majority ownership in the company. diaDexus provided an exclusive license to CFD for its entire portfolio of therapeutic targets and associated monoclonal antibodies. CFD's programs will leverage over eight years and $100 million of target discovery and antibody development efforts carried out at diaDexus. Through its founding partnership with Incyte Genomics in 1997 and its own discovery program, diaDexus identified genes that are highly over-expressed in cancerous relative to normal tissue. Starting from thousands of candidate genes, diaDexus identified approximately 20 promising candidates to move forward into pre-clinical development as t... Northwest Biotherapeutics Announces $5.5 Million Private Placement ...... SOURCE Northwest Biotherapeutics, Inc. Web Site: http://www.nwbio.com Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.Terms and conditions, including restrictions on redistribution, apply. Copyright © 1996- PR Newswire Association LLC. All Rights Reserved. A United Business Media company. ... 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | All news |
| Best Cancer Care |